GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), based in Paris, France, have announced the publication of updated efficacy results from a pooled analysis of… Read More »GenSight Biologics announces a pooled presentation of LUMEVOQ versus natural history in ND4-LHON.
Researchers at the Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, have reported that outcome measures for future clinical trials should include evaluations… Read More »Outcome measures for future trials for autosomal dominant vitelliform macular dystrophy caused by BEST1 mutations.
Researchers at the Seoul National University College of Medicine, Republic of Korea, have demonstrated a proof-of-principle using “base editing” (BEs) to address Leber congenital amaurosis… Read More »Visual function restoration for a pre-clinical in vivo IRD model using a novel therapeutic “base editing”.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 30th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »January 30th, 2023 “EURETINA-Brief”© Issue No. 265
A French bioelectronics company “Pixium Vision SA” (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), based in Paris, has announced the completion of implantations of an… Read More »Pixium SA has announced the completion of implantations of the “PRIMAvera” trial with the implantation of a bionic artificial retina.
Researchers at the UCL Institute of Ophthalmology, London and Moorfields Eye Hospital NHS Foundation Trust has reported a novel history of RP2 mutations arising from… Read More »A natural history of XLRP from RP2 mutations aim to facilitate trial endpoints for future clinical studies.
A systematic review on the epidemiology of RPE65 mutations reported in the literature showed that there were significant variations of RPE65 proportions within countries as… Read More »A systematic literature review on the epidemiology of RPE65 mutations report significant variations in the literature within countries as well as regions.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 8th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »January 8th, 2023 “EURETINA-Brief”© Issue No. 264
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the FDA clearance of its Investigational New Drug (IND)… Read More »Opus Genetics Inc., has announced an IND application for “OPGx-001” for the treatment of LCA5 retinal disease
An interim analysis from a Phase II study for a novel peptide (THR-149) is aimed to prevent the induction of retinal vascular permeability, neurodegeneration and… Read More »Phase II data on a novel peptide candidate – plasma kallikrein (PKal) (THR-149) – for treatment of diabetic macular edema (DME)